XML 49 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Subsidiary Bankruptcy and Deconsolidation
12 Months Ended
Dec. 31, 2021
Reorganizations [Abstract]  
Subsidiary Bankruptcy and Deconsolidation Subsidiary Bankruptcy and Deconsolidation
On February 6, 2019, the Company deconsolidated Specialty Pharma effective with the filing of the Chapter 11 bankruptcy and recorded a non-cash charge of approximately $2,678 for the year ended December 31, 2019.

The Company recognized a non-cash gain of $217 and $3,364 from the release of certain liabilities that had been retained following the deconsolidation of Specialty Pharma. These gains are included in "Gain from release of certain liabilities" within non-operating (loss) income for the years ended December 31, 2021 and 2020.
On October 26, 2021, the U.S. Bankruptcy Court for the District of Delaware issued the Final Decree and Order, dismissing the bankruptcy case and dissolving Specialty Pharma.